Evaluation of Patients Treated With HMG-CoA Reductase Inhibitors to Reach Cholesterol Target Values

Study Overview
=================
Brief Summary
-----------------
This study is non-interventional study of patients who are treated with any HMGCoA reductase inhibitors (rosuvastatin, simvastatin,atorvastatin and fluvastatin) available in Bosnia and Herzegovina for at least 6 months. Data collection for each patient will take place at a single visit. The investigators will complete Case Report Form (CRF) with patient's demographic, the presence of the factors for high cardiovascular risk, current treatment, cholesterol value as well as with further treatment decision.

Detailed Description
-----------------
Non-interventional study to assess reaching of cholesterol target values in patients treated with HMG-CoA reductase inhibitors in Bosnia and Herzegovina

Official Title
-----------------
Non-interventional Study to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors in Bosnia and Herzegovina

Conditions
-----------------
Hypercholesterolaemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients, treated with one HMG-CoA reductase inhibitors for at least 6 months without changing the dose for the last 4 weeks at least All patients must sign informed consent form Exclusion Criteria: Patients who have not signed the Informed Consent Form Patients with contraindication for the treatment with HMG-CoA reductase inhibitors as per SmPC approved in Bosnia and Herzegovina

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with hypercholesterolaemia<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number and percentage of patients reaching the LDL-C goals, according to the Fourth Joint European Task Force guideline. |  | During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number and percentage of patients reaching the total cholesterol goals, according to the Fourth Joint European Task Force guideline. |  | During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated | 
| The number and percentage of patients with high cardiovascular risk reaching the LDL-C goals, according to the Fourth Joint European Task Force guideline. |  | During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated | 
| The number and percentage of patients with high cardiovascular risk reaching the total cholesterol goals, according to the Fourth Joint European Task Force guideline. |  | During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dyslipidemia, Statins, Total Cholesterol, Low density lipoprotein (LDL) cholesterol, High density lipoprotein (HDL) cholesterol